Sure, no problem. Quite simplistic and it’s based on both accepted estimates as well as some of my own assumptions. Also assumes we will get FDA approval in 2 years from now.
The estimated TAM for radiopharm diagnostics in 2 years from now is approximately $3B. Assuming the H2H is favourable which I’m confident it will be, I estimate that Clarity will get at least 2 thirds of the market if not more. So that’s $2B in revenue. Place an ultra conservative multiple of 3x on that revenue and you get a valuation of $6B. Divide that by approximately 315M shares on issue and you end up with about $19 per share for diagnostics alone.
So I said $15 just in case my assumptions are a bit out or in the unlikely event our supply contracts can’t meet the huge demand that will be required. All amounts are in USD by the way so do the FX conversion and it’s considerably more.
CU6 Price at posting:
$1.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)